194
Results-
NewsPierre Fabre Laboratories Begins Next Chapter in Secaucus, NJCreated on : - Last modified on :SECAUCUS, NJ (June 18, 2025): Pierre Fabre Laboratories, a global healthcare company originated from France, announces the inauguration of its new US office located on 500 Plaza Drive, in Secaucus, NJ which will host its dermo-cosmetics and medical care subsidiaries. Pierre Fabre is the world’s second-largest dermo-cosmetics manufacturer and a global player in oncology, cell & gene therapy, rare disease and dermatology.
-
Disclosure of Payments to Patient OrganisationsCreated on : - Last modified on :Disclosure of Payments to Patient Organisations Patient organizations provide a powerful voice for patients across Europe. They aim at improving the quality of life of people who suffer from diseases. They are an emotional support for patients, they help them and their carriers to better understand their illness and their care.
-
NewsPierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241Created on : - Last modified on :PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed as treatment options for emergent and unmet medical needs in non-small cell lung cancer ("NSCLC")
-
NewsThe 2025 Annual Report, under the sign of a new energyCreated on : - Last modified on :Find the 2025 annual report (2024 figures) online.
-
NewsroomCreated on : - Last modified on :
-
Annual Report 2025 of Laboratories Pierre FabreCreated on : - Last modified on :
-
Press ReleaseLicense and Commercialization agreement between Pierre Fabre and ValenzaBio on an anti-IGF-1R antibody for the development of a novel treatment in Thyroid Eye Disease (TED)Created on : - Last modified on :
-
Press ReleaseY-Biologics and Pierre Fabre confirms their research collaboration for the development of new immunotherapies in oncologyCreated on : - Last modified on :Daejeon (South Korea), Castres (France), March 29th, 2021 – The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre announce the conclusion of a strategic Research Collaboration & Optional License Agreement concerning several targets in the field of immuno-oncology.
-
Press Release1962-2022: THE PIERRE FABRE GROUP CELEBRATES ITS 60TH ANNIVERSARYCreated on : - Last modified on :Castres, May 23, 2022 - Founded on May 30, 1962 in Castres by a young pharmacist, an entrepreneur at heart and a botany enthusiast, the Pierre Fabre Group is preparing to celebrate its 60th anniversary. For six decades, without ever denying its Occitan roots, Pierre Fabre has become a world-class player in oncology, dermatology and dermo-cosmetics.
-
Press ReleasePierre Fabre becomes the first international manufacturing group to be awarded the “Outstanding” level of the Responsibility Europe label delivered by AFNOR CertificationCreated on : - Last modified on :Castres, September 28, 2022. The Pierre Fabre Group’s social and environmental responsibility policy has just been awarded the “Outstanding” level of the Responsibility Europe label from independent certification body AFNOR Certification. Pierre Fabre’s overall score of 788 points out of 1,000 means that the Group belongs to the top 1% of the 266 companies audited to-date by AFNOR Certification. It becomes the first international manufacturing group with more than 5,000 employees to obtain the “Outstanding” level of the label.
We take care of life by designing and developing innovative solutions inspired by consumers and patients, and contributing to the well-being of everyone from health to beauty.